Risk of All-Cause Mortality in Mild Chronic Obstructive Pulmonary Disease: Evidence From the NHANES III and 2007-2012.

IF 3.1 3区 医学 Q2 RESPIRATORY SYSTEM International Journal of Chronic Obstructive Pulmonary Disease Pub Date : 2025-01-30 eCollection Date: 2025-01-01 DOI:10.2147/COPD.S497634
Weifeng Zou, Jie Ou, Fan Wu, Shan Xiao, Zhishan Deng, Haiqing Li, Zihui Wang, Gaoying Tang, Shuling Liu, Dong Ye, Dongshuang Zhu, Jinxing Hu, Pixin Ran
{"title":"Risk of All-Cause Mortality in Mild Chronic Obstructive Pulmonary Disease: Evidence From the NHANES III and 2007-2012.","authors":"Weifeng Zou, Jie Ou, Fan Wu, Shan Xiao, Zhishan Deng, Haiqing Li, Zihui Wang, Gaoying Tang, Shuling Liu, Dong Ye, Dongshuang Zhu, Jinxing Hu, Pixin Ran","doi":"10.2147/COPD.S497634","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It is unclear whether patients with Global Initiative for Chronic Obstructive Lung Disease stage 1 (mild) chronic obstructive pulmonary disease (COPD) have a higher risk of all-cause mortality than participants with normal spirometry results.</p><p><strong>Methods: </strong>We used the data from the National Health and Nutrition Examination Survey (NHANES) III and 2007-2012, which included participants aged 20-79 years, to investigate whether patients with mild COPD (whole population and subgroups) have a higher risk of all-cause mortality than participants with normal spirometry. Mild COPD was defined as prebronchodilator forced expiratory volume in 1 second /forced vital capacity <0.70 and FEV<sub>1</sub> ≥80% of the predicted value. All-cause mortality risk is the total risk of death from all causes over a given period of time. We performed subgroup analyses by sex, age, smoking status, race, body mass index, and level of education. We also performed sensitivity analyses using the lower limit of normal to define COPD.</p><p><strong>Results: </strong>1,760 patients (64.5% male; median aged 59 years) with mild COPD and 19,969 participants with normal spirometry (46.9% male; median aged 43 years) were followed up (median 308 months). Patients with mild COPD had a higher all-cause mortality risk than participants with normal spirometry (adjusted: Hazard Ratios 1.13, 95% Confidence Intervals 1.04-1.23; P = 0.005). The results remained robust in the sensitivity analyses. The subgroup analyses results for male sex, age ≥50 years, and current smokers were consistent with the main analysis.</p><p><strong>Conclusion: </strong>Patients with mild COPD had a higher all-cause mortality risk than those with normal spirometry, especially males, those aged ≥50 years, and current smokers. These results suggest the need for appropriate management of different subgroups with mild COPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"217-229"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789505/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S497634","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: It is unclear whether patients with Global Initiative for Chronic Obstructive Lung Disease stage 1 (mild) chronic obstructive pulmonary disease (COPD) have a higher risk of all-cause mortality than participants with normal spirometry results.

Methods: We used the data from the National Health and Nutrition Examination Survey (NHANES) III and 2007-2012, which included participants aged 20-79 years, to investigate whether patients with mild COPD (whole population and subgroups) have a higher risk of all-cause mortality than participants with normal spirometry. Mild COPD was defined as prebronchodilator forced expiratory volume in 1 second /forced vital capacity <0.70 and FEV1 ≥80% of the predicted value. All-cause mortality risk is the total risk of death from all causes over a given period of time. We performed subgroup analyses by sex, age, smoking status, race, body mass index, and level of education. We also performed sensitivity analyses using the lower limit of normal to define COPD.

Results: 1,760 patients (64.5% male; median aged 59 years) with mild COPD and 19,969 participants with normal spirometry (46.9% male; median aged 43 years) were followed up (median 308 months). Patients with mild COPD had a higher all-cause mortality risk than participants with normal spirometry (adjusted: Hazard Ratios 1.13, 95% Confidence Intervals 1.04-1.23; P = 0.005). The results remained robust in the sensitivity analyses. The subgroup analyses results for male sex, age ≥50 years, and current smokers were consistent with the main analysis.

Conclusion: Patients with mild COPD had a higher all-cause mortality risk than those with normal spirometry, especially males, those aged ≥50 years, and current smokers. These results suggest the need for appropriate management of different subgroups with mild COPD.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
轻度慢性阻塞性肺疾病的全因死亡率风险:来自NHANES III和2007-2012的证据
背景:目前尚不清楚全球慢性阻塞性肺疾病倡议1期(轻度)慢性阻塞性肺疾病(COPD)患者的全因死亡率是否高于肺活量测定结果正常的参与者。方法:我们使用来自国家健康与营养调查(NHANES) III和2007-2012年的数据,其中包括20-79岁的参与者,调查轻度COPD患者(整个人群和亚组)是否比正常肺活量测定的参与者具有更高的全因死亡率风险。轻度COPD定义为支气管扩张前1秒用力呼气量/用力肺活量1≥预测值的80%。全因死亡风险是指在一定时期内所有原因造成的总死亡风险。我们按性别、年龄、吸烟状况、种族、体重指数和教育水平进行亚组分析。我们还使用正常下限来定义COPD进行了敏感性分析。结果:1760例患者(男性64.5%;中位年龄59岁)轻度COPD患者和19,969名肺功能正常的参与者(46.9%为男性;中位年龄43岁),随访时间中位308个月。轻度COPD患者的全因死亡风险高于肺量正常的受试者(调整后:风险比1.13,95%置信区间1.04-1.23;P = 0.005)。结果在敏感性分析中仍然是稳健的。男性、年龄≥50岁和当前吸烟者的亚组分析结果与主分析一致。结论:轻度COPD患者的全因死亡风险高于肺量测定正常的患者,尤其是男性、年龄≥50岁的患者和当前吸烟者。这些结果表明需要对不同亚组轻度COPD患者进行适当的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
期刊最新文献
Mechanical Forces and Mechanotransduction in COPD: Pathogenesis, Clinical Phenotypes, and Therapeutic Implications. A Nomogram for Predicting 5-Year Risk of New-Onset Type 2 Diabetes in Patients with COPD: A Two-Center Retrospective Cohort Study. A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards. Pulmonary-Intestinal Axis: Shared Genetic Basis and Mediating Factors Identified Through Multi-Omics Analysis. Participation of miRNA-23a-3p in Pulmonary Tuberculosis Through Macrophages via the JAK-STAT Pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1